The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Open accessAbstract
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“High-throughput genomic, epigenomic, and transcriptomic profiling of glioblastoma cells revealed three main subtypes harboring distinct molecular and phenotypic landscapes that affect response to the therapy and clinical outcome: mesenchymal, proneural, and classical subtypes.96,97,98,99,100”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, IDH mutant gliomas strongly express PDGFRA (Fig. 2b), and share the proneural transcriptional program characteristic of PDGFRA-amplified tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of p53 mutations differs in the different GBM molecular subtypes (proneural, mesenchymal, neural and classical) (54%, 32%, 21% and 0%, respectively) [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crucially, the levels of miR-128-3p forms can also differ depending on the genetic and molecular background, as they correlated with the glioblastoma subtypes, with the most reduced expression in the most aggressive mesenchymal one.96,113”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, upregulation of PDGFRA, platelet-derived growth factor receptor alpha, is a hallmark of the proneural subtype [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
In the citing paper
“While glioblastoma is the most common malignant primary brain tumor26–28, it is still classified as a “rare” disease, as its incidence rate (i.e., 3/100,000 people) is substantially lower than the rare disease definition rate (i.e., <10/100,000 people)24.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silhouettes: A graphical aid to the interpretation and validation of cluster analysis
Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F. Z., Miled, S. B., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,785
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,837
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,022
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169
Parker, N., Hudson, A. L., Khong, P., Parkinson, J., Dwight, T., Ikin, R. J., Zhu, Y., Cheng, Z. J., Vafaee, F., Chen, J., et al. (2016) · Scientific Reports · doi:10.1038/srep22477 · Cited by 183
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
Cosset, E. C., Ilmjärv, S., Dutoit, V., Elliott, K. C., Schalscha, T. V., Camargo, M. F., Reiss, A., Moroishi, T., Seguin, L., Gomez, G. G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.016 · Cited by 172
Self-citationPaul, R., Dorsey, J. F., & Fan, Y. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107985 · Cited by 170
The Metabolomic Signature of Malignant Glioma Reflects Accelerated Anabolic Metabolism
Chinnaiyan, P., Kensicki, E., Bloom, G. C., Prabhu, A. H., Sarcar, B., Kahali, S., Eschrich, S. A., Qu, X., Forsyth, P. A., & Gillies, R. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1572-t · Cited by 172
A Review of Newly Diagnosed Glioblastoma
Oronsky, B. T., Reid, T. R., Oronsky, A. L., Sandhu, N., & Knox, S. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574012 · Cited by 177
Yes-Associated Protein 1 Is Widely Expressed in Human Brain Tumors and Promotes Glioblastoma Growth
Orr, B. A., Bai, H., Odia, Y., Jain, D., Anders, R. A., & Eberhart, C. G. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31821ff8d8 · Cited by 167
Emerging Therapies for Glioblastoma
Thomas, A. A., Brennan, C., DeAngelis, L. M., & Omuro, A. M. P. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1701 · Cited by 173
Self-citationThe cancer stem cell niche(s): The crosstalk between glioma stem cells and their microenvironment
Filatova, A., Acker, T., & Garvalov, B. K. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.10.008 · Cited by 178
Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis
Brown, C. E., Warden, C., Starr, R., Deng, X., Badie, B., Yuan, Y., Forman, S. J., & Barish, M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077769 · Cited by 171
Genetic profile of astrocytic and oligodendroglial gliomas
Ohgaki, H., & Kleihues, P. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-011-0029-1 · Cited by 167
Sox2 Promotes Malignancy in Glioblastoma by Regulating Plasticity and Astrocytic Differentiation
Berezovsky, A. D., Poisson, L., Cherba, D., Webb, C. P., Transou, A. D., Lemke, N. W., Hong, X., Hasselbach, L. A., Irtenkauf, S. M., Mikkelsen, T., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.03.006 · Cited by 167
Qiu, S., Lin, S., Hu, D., Feng, Y., Tan, Y., & Peng, Y. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-10 · Cited by 169
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 180
Schreck, K. C., Taylor, P. H., Marchionni, L., Gopalakrishnan, V., Bar, E. E., Gaiano, N., & Eberhart, C. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1624 · Cited by 169
Radioresistance in Glioblastoma and the Development of Radiosensitizers
Ali, M. Y., Oliva, C. R., Noman, A. S. M., Allen, B. G., Goswami, P. C., Zakharia, Y., Monga, V., Spitz, D. R., Buatti, J. M., & Griguer, C. E. (2020) · Cancers · doi:10.3390/cancers12092511 · Cited by 183
NF-κB-Induced IL-6 Ensures STAT3 Activation and Tumor Aggressiveness in Glioblastoma
McFarland, B. C., Hong, S. W., Rajbhandari, R., Twitty, G. B., Gray, G. K., Yu, H., Benveniste, E. N., & Nozell, S. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078728 · Cited by 170
ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma
Tong, L., Li, J., Li, Q., Wang, X., Medikonda, R. T., Zhao, T., Li, T., Ma, H., Li, Y., Liu, P., et al. (2020) · Theranostics · doi:10.7150/thno.41498 · Cited by 166
Boja, E. S., & Rodriguez, H. (2012) · PROTEOMICS · doi:10.1002/pmic.201100387 · Cited by 166
Mahabir, R., Tanino, M. A., Elmansuri, A., Wang, L., Kimura, T., Itoh, T., Ohba, Y., Nishihara, H., Shirato, H., Tsuda, M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not239 · Cited by 170
The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma
Venere, M., Horbinski, C., Crish, J. F., Jin, X., Vasanji, A., Major, J. A., Burrows, A. C., Chang, C., Prokop, J., Wu, Q., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6762 · Cited by 162
Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy
Anwar, S., Shamsi, A., Mohammad, T., Islam, A., & Hassan, M. I. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188568 · Cited by 168
Babić, I., Anderson, E. S., Tanaka, K., Guo, D., Masui, K., Li, B., Zhu, S., Gu, Y., Villa, G. R., Akhavan, D., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.013 · Cited by 169
CAMTA1 is a novel tumour suppressor regulated by miR‐9/9* in glioblastoma stem cells
Schraivogel, D., Weinmann, L., Beier, D., Tabatabai, G., Eichner, A., Zhu, J. Y., Anton, M., Sixt, M., Weller, M., Beier, C. P., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.301 · Cited by 170
Quantification of cell identity from single-cell gene expression profiles
Efroni, I., Ip, P.-L., Nawy, T., Mello, A. J., & Birnbaum, K. D. (2015) · Genome biology · doi:10.1186/s13059-015-0580-x · Cited by 163
Gielen, P. R., Schulte, B. M., Kers‐Rebel, E. D., Verrijp, K. C. N., Bossmann, S. A. J. F. H., ter Laan, M., Wesseling, P., & Adema, G. J. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now034 · Cited by 164
The role of CD44 in glioblastoma multiforme
Mooney, K. L., Choy, W., Sidhu, S., Pelargos, P. E., Bui, T. T., Voth, B. L., Barnette, N. E., & Yang, I. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.05.012 · Cited by 164
Cui, X., Ma, C., Vasudevaraja, V., Serrano, J., Tong, J., Peng, Y., DeLorenzo, M., Shen, G., Frenster, J. D., Morales, R. T., et al. (2020) · eLife · doi:10.7554/elife.52253 · Cited by 163
Personalized Medicine: Marking a New Epoch in Cancer Patient Management
Diamandis, M., White, N. M. A., & Yousef, G. M. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0264 · Cited by 170
MET in glioma: signaling pathways and targeted therapies
Cheng, F., & Guo, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1269-x · Cited by 167
The CRISPR‐Cas13a Gene‐Editing System Induces Collateral Cleavage of RNA in Glioma Cells
Wang, Q., Liu, X., Zhou, J., Yang, C., Wang, G., Tan, Y., Wu, Y., Zhang, S., Yi, K., & Kang, C. (2019) · Advanced Science · doi:10.1002/advs.201901299 · Cited by 158
Integrin Signaling in Glioma Pathogenesis: From Biology to Therapy
Ellert‐Miklaszewska, A., Poleszak, K., Pasierbińska, M., & Kaminska, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030888 · Cited by 170
Increased Microglia/Macrophage Gene Expression in a Subset of Adult and Pediatric Astrocytomas
Engler, J. R., Robinson, A. E., Smirnov, I. V., Hodgson, J. G., Berger, M. S., Gupta, N. M., James, C. D., Molinaro, A. M., & Phillips, J. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043339 · Cited by 167
Self-citationSexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males
Sun, T., Warrington, N. M., Luo, J. R., Brooks, M. D., Dahiya, S. M., Snyder, S. C., Sengupta, R., & Rubin, J. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71048 · Cited by 162
Cell of origin of glioma: biological and clinical implications
Llaguno, S. R. A., & Parada, L. F. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.354 · Cited by 176
Zhang, P., Qin, X., Liu, L., Li, S., & Dong, L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.562798 · Cited by 169
A prognostic gene expression signature in infratentorial ependymoma
Wani, K., Armstrong, T. S., Vera‐Bolanos, E., Raghunathan, A., Ellison, D. W., Gilbertson, R. J., Vaillant, B. D., Goldman, S., Packer, R. J., Fouladi, M., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0941-4 · Cited by 161
Updated Insights on EGFR Signaling Pathways in Glioma
Oprița, A., Baloi, C., Staicu, G.-A., Alexandru, O., Tache, D. E., Dănoiu, S., Micu, E. S., & Sevastre, A.-S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020587 · Cited by 167
Leblanc, V., Trinh, D. L. N., Aslanpour, S., Hughes, M. L., Livingstone, D., Jin, D., Ahn, B. Y., Blough, M. D., Cairncross, J. G., Chan, J. A.-W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2022.02.016 · Cited by 159
MET Signaling Regulates Glioblastoma Stem Cells
Joo, K. M., Jin, J., Kim, E. H., Kim, K. H., Kim, Y., Kang, B. G., Kang, Y.-J., Lathia, J. D., Cheong, K. H., Song, P. H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3760 · Cited by 164
A tension-mediated glycocalyx–integrin feedback loop promotes mesenchymal-like glioblastoma
Barnes, J. M., Kaushik, S., Bainer, R. O., Sa, J. K., Woods, E. C., Kai, F., Przybyla, L., Lee, M., Lee, H. W., Tung, J. C., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0183-3 · Cited by 169
Khalsa, J. K., Cheng, N. H., Keegan, J., Chaudry, A. E., Driver, J., Bi, W. L., Lederer, J. A., & Shah, K. (2020) · Nature Communications · doi:10.1038/s41467-020-17704-5 · Cited by 161
Golebiewska, A., Hau, A., Oudin, A., Stieber, D., Yabo, Y. A., Baus, V., Barthelemy, V., Klein, E., Bougnaud, S., Keunen, O., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02226-7 · Cited by 161
Masica, D. L., & Karchin, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0180 · Cited by 162
Surgical resection of malignant gliomas—role in optimizing patient outcome
Eyüpoglu, I. Y., Buchfelder, M., & Savaskan, N. E. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.279 · Cited by 166
M3C: Monte Carlo reference-based consensus clustering
John, C. R., Watson, D., Russ, D., Goldmann, K., Ehrenstein, M. R., Pitzalis, C., Lewis, M., & Barnes, M. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-58766-1 · Cited by 159
dbEMT: an epithelial-mesenchymal transition associated gene resource
Zhao, M., Kong, L., Liu, Y., & Qu, H. (2015) · Scientific Reports · doi:10.1038/srep11459 · Cited by 156
Serres, É., Debarbieux, F. C., Stanchi, F., Maggiorella, L., Grall, D., Turchi, L., Burel‐Vandenbos, F., Figarella‐Branger, D., Virolle, T., Rougon, G., et al. (2013) · Oncogene · doi:10.1038/onc.2013.305 · Cited by 169
Mehta, S. V., Huillard, E., Kesari, S., Maire, C. L., Golebiowski, D., Harrington, E. P., Alberta, J. A., Kane, M., Theisen, M., Ligon, K. L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.035 · Cited by 165
Gullapalli, R. R., Desai, K., Santana‐Santos, L., Kant, J. A., & Becich, M. J. (2012) · Journal of Pathology Informatics · doi:10.4103/2153-3539.103013 · Cited by 169
Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types
Wang, C., Gu, Y., Zhang, K., Xie, K., Zhu, M., Dai, N., Jiang, Y., Guo, X., Liu, M., Dai, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10499 · Cited by 161
Brown, D. V., Filiz, G., Daniel, P. M., Hollande, F., Dworkin, S., Amiridis, S., Kountouri, N., Ng, W., Morokoff, A. P., & Mantamadiotis, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172791 · Cited by 166
Dissecting and rebuilding the glioblastoma microenvironment with engineered materials
Wolf, K. J., Chen, J., Coombes, J. D., Aghi, M. K., & Kumar, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0135-y · Cited by 164
Vigneswaran, K., Neill, S. G., & Hadjipanayis, C. G. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.57 · Cited by 157
Biomarkers and therapeutic advances in glioblastoma multiforme
Sasmita, A. O., Wong, Y. P., & Ling, A. P. K. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12756 · Cited by 167
Jonsson, P., Lin, A. L., Young, R. J., DiStefano, N. M., Hyman, D. M., Li, B. T., Berger, M. F., Zehir, A., Ladanyi, M., Solit, D. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0032 · Cited by 156
Self-citationSubtype-GAN: a deep learning approach for integrative cancer subtyping of multi-omics data
Yang, H., Chen, R., Li, D., & Wang, Z. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab109 · Cited by 157
Yang, D., Rao, G., Martinez, J. J., Veeraraghavan, A., & Rao, A. U. K. (2015) · Medical Physics · doi:10.1118/1.4934373 · Cited by 160
Clinically Relevant Molecular Subtypes in Leiomyosarcoma
Guo, X., Jo, V. Y., Mills, A. M., Zhu, S., Lee, C., Espinosa, Í., Nucci, M. R., Varma, S., Forgó, E., Hastie, T. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3141 · Cited by 156
GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity
Vartanian, A., Singh, S. K., Agnihotri, S., Jalali, S., Burrell, K. E., Aldape, K., & Zadeh, G. M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou035 · Cited by 158
Avoiding common pitfalls when clustering biological data
Ronan, T., Qi, Z., & Naegle, K. M. (2016) · Science Signaling · doi:10.1126/scisignal.aad1932 · Cited by 155
Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy
Bastola, S., Pavlyukov, M. S., Yamashita, D., Ghosh, S., Cho, H., Kagaya, N., Zhang, Z., Minata, M., Lee, Y., Sadahiro, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18189-y · Cited by 160
Efficient methods for identifying mutated driver pathways in cancer
Zhao, J., Zhang, S., Wu, L., & Zhang, X.-S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts564 · Cited by 155
Kim, S.-H., Ezhilarasan, R., Phillips, E. S., Gallego‐Perez, D., Sparks, A. E., Taylor, D., Ladner, K. J., Furuta, T., Sabit, H., Chhipa, R. R., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.005 · Cited by 159
Zhang, X., Rao, A., Sette, P., Deibert, C., Pomerantz, A., Kim, W. J., Kohanbash, G., Chang, Y., Park, Y., Engh, J. A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now061 · Cited by 161
Rathore, S., Akbari, H., Rozycki, M., Abdullah, K. G., Nasrallah, M. P., Binder, Z. A., Davuluri, R. V., Lustig, R. A., Dahmane, N., Bilello, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22739-2 · Cited by 162
Kaffes, I., Szulzewsky, F., Chen, Z., Herting, C. J., Gabanic, B., Vega, J. E. V., Shelton, J., Switchenko, J. M., Ross, J., McSwain, L., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655360 · Cited by 151
Self-citationLucero, R., Zappulli, V., Sammarco, A., Murillo, O. D., Cheah, P.-S., Srinivasan, S., Tai, E. C., Ting, D. T., Wei, Z., Roth, M. E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.073 · Cited by 157
PRADA: pipeline for RNA sequencing data analysis
Torres‐García, W., Zheng, S., Sivachenko, A., Vegesna, R., Wang, Q., Yao, R., Berger, M. F., Weinstein, J. N., Getz, G. A., & Verhaak, R. G. W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu169 · Cited by 158
Self-citationiBAG: integrative Bayesian analysis of high-dimensional multiplatform genomics data
Wang, W., Baladandayuthapani, V., Morris, J. S., Broom, B. M., Manyam, G. C., & Do, K.-A. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts655 · Cited by 154
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 154
Patient Similarity Networks for Precision Medicine
Pai, S., & Bader, G. D. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.037 · Cited by 159
Molecular subtyping of cancer: current status and moving toward clinical applications
Zhao, L., Lee, V. H.-F., Ng, M. K., Yan, H., & Bijlsma, M. F. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby026 · Cited by 156
The adaptive transition of glioblastoma stem cells and its implications on treatments
Wang, Z., Zhang, H., Xu, S., Liu, Z., & Cheng, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00491-w · Cited by 163
Duan, W., Yang, L., Liu, J., Dai, Z., Wang, Z., Zhang, H., Zhang, X., Liang, X., Luo, P., Zhang, J., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14489 · Cited by 156
Soroceanu, L., Murase, R., Limbad, C., Singer, E. A., Allison, J., Adrados, I., Kawamura, R., Pakdel, A., Fukuyo, Y., Nguyen, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1943 · Cited by 151
Patient-Derived Glioma Models: From Patients to Dish to Animals
da Hora, C. C., Schweiger, M. W., Würdinger, T., & Tannous, B. A. (2019) · Cells · doi:10.3390/cells8101177 · Cited by 154
Central nervous system gliomas
Reni, M., Mazza, E. A., Zanon, S. M., Gatta, G., & Vecht, C. J. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.021 · Cited by 158
Revisiting Telomere Shortening in Cancer
Okamoto, K., & Seimiya, H. (2019) · Cells · doi:10.3390/cells8020107 · Cited by 161
Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target
Garnier, D., Renoult, O., Alves‐Guerra, M., Paris, F., & Pecqueur, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00118 · Cited by 161
Jin, X., Jeon, H.-Y., Joo, K. M., Kim, J.-K., Jin, J., Kim, S.-H., Kang, B. G., Beck, S. J., Lee, S. J., Kim, J. K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1495 · Cited by 156
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts
Cho, S., Kang, W., Han, J. Y., Min, S., Kang, J., Lee, A., Kwon, J. Y., Lee, C., & Park, H. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2350 · Cited by 152
The emergent role of exosomes in glioma
Gourlay, J., Morokoff, A. P., Luwor, R. B., Zhu, H., Kaye, A. H., & Stylli, S. S. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.09.021 · Cited by 153
The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer
Krogan, N. J., Lippman, S. M., Agard, D. A., Ashworth, A., & Ideker, T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.008 · Cited by 154
Bardella, C., Al‐Dalahmah, O., Krell, D., Brazauskas, P., Al‐Qahtani, K., Tomková, M., Adam, J., Serres, S., Lockstone, H. E., Freeman-Mills, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.017 · Cited by 157
Meng, X., Zhao, Y., Han, B. R., Zha, C., Zhang, Y., Li, Z., Wu, P., Qi, T., Jiang, C., Liu, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14036-x · Cited by 149
Tumor vasculature and glioma stem cells: Contributions to glioma progression
Jhaveri, N., Chen, T. C., & Hofman, F. M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.028 · Cited by 154
Lei, L., Sonabend, A. M., Guarnieri, P., Soderquist, C. R., Ludwig, T. E., Rosenfeld, S. A., Bruce, J. N., & Canoll, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020041 · Cited by 149
Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
Daniel, P. M., Sabri, S., Chaddad, A., Meehan, B., Jean‐Claude, B. J., Rak, J. W., & Abdulkarim, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00041 · Cited by 152
Cooper, L., Gutman, D. A., Long, Q., Johnson, B. A., Cholleti, S. R., Kurç, T., Saltz, J. H., Brat, D. J., & Moreno, C. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012548 · Cited by 152
Mao, X., Xue, X., Wang, L., Zhang, X., Yan, M., Tu, Y.-Y., Lin, W., Jiang, X., Ren, H., Zhang, W., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not029 · Cited by 151
Liu, J., Gao, L., Zhan, N., Xu, P., Yang, J., Yuan, F., Xu, Y., Cai, Q., Geng, R., & Chen, Q. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01641-8 · Cited by 148
Perspective of mesenchymal transformation in glioblastoma
Kim, Y., Varn, F. S., Park, S., Yoon, B. W., Park, H. R., Lee, C., Verhaak, R. G. W., & Paek, S. H. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01151-4 · Cited by 152
Self-citationThe Interplay between Glioblastoma and Its Microenvironment
Dapash, M., Hou, D., Castro, B. A., Lee-Chang, C., & Lesniak, M. S. (2021) · Cells · doi:10.3390/cells10092257 · Cited by 159
Cloughesy, T. F., Finocchiaro, G., Belda-Iniesta, C., Recht, L. D., Brandes, A. A., Pineda, E., Mikkelsen, T., Chinot, O. L., Balañá, C., Macdonald, D. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.7685 · Cited by 150
Emerging Insights into Barriers to Effective Brain Tumor Therapeutics
Woodworth, G. F., Dunn, G. P., Nance, E. A., Hanes, J. S., & Brem, H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00126 · Cited by 153
Li, J., Zhu, S., Kozono, D., Ng, K., Futalan, D., Shen, Y. H., Akers, J. C., Steed, T., Kushwaha, D. S., Schlabach, M. R., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1801 · Cited by 147
Glioblastoma: Therapeutic challenges, what lies ahead
Lima, F. R. S., Kahn, S. A., Soletti, R. C., Biasoli, D., Alves, T. R., da Fonseca, A. C. C., Garcia, C., Romão, L. F., Brito, J. M., Afonso, R. C. D. H., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.05.004 · Cited by 148
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance
Garros-Regulez, L., Aldaz, P., Arrizabalaga, O., Moncho-Amor, V., Carrasco‐García, E., Manterola, L., Moreno‐Cugnon, L., Barrena, C., Villanúa, J., Ruiz, I., et al. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1151002 · Cited by 150
The Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 149
Metadata
- Authors
- Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H. S., Hodgson, J. G., James, C. D., Sarkaria, J. N., Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. P., Gray, J. W., Meyerson, M., Getz, G., Perou, C. M., & Hayes, D. N.
- Affiliations
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Berkeley (US)
- Washington University in St. Louis (US)
- Lawrence Berkeley National Laboratory (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- SRA International (United States) (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Hayes, D. Neil
- ORCID
- Verhaak, Roel G.W.
- Hoadley, Katherine A.
- Purdom, Elizabeth
- Wang, Victoria
- Qi, Yuan
- Wilkerson, Matthew D.
- Miller, C. Ryan
- Ding, Li
- Golub, Todd
- Mesirov, Jill P.
- Lawrence, Michael
- Tamayo, Pablo
- Gabriel, Stacey
- Winckler, Wendy
- Gupta, Supriya
- Feiler, Heidi S.
- Hodgson, J. Graeme
- James, C. David
- Sarkaria, Jann N.
- Brennan, Cameron
- Spellman, Paul T.
- Wilson, Richard K.
- Speed, Terence P.
- Gray, Joe W.
- Meyerson, Matthew
- Getz, Gad
- Perou, Charles M.
- Hayes, D. Neil
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 17
- Issue
- 1
- Pages
- 98-110
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2818769
- OpenAlex
- W2161289668
- Cited by
- 7,575
- References
- 52
- Citations by year
- 2026: 312 · 2025: 399 · 2024: 451 · 2023: 551 · 2022: 523 · 2021: 697 · 2020: 593 · 2019: 493 · 2018: 482 · 2017: 522 · 2016: 502 · 2015: 455 · 2014: 459 · 2013: 406 · 2012: 379
- FWCI
- 159.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Energy
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (CA097257, L30 CA104183, U24CA126554, R01CA127716, CA108961, U24CA126546, U24CA126543, U24CA126563, U24CA126544, U24CA143867, U24CA143848, P50CA108961, U24CA126551, CA127716, P50 CA 58223, U24CA126561, P50CA058223, P50CA097257)
- National Institute of Neurological Disorders and Stroke (R01NS049720, NS49720)
- National Institute of Environmental Health Sciences (F30ES019449)
- National Center for Research Resources (RR023248, K12RR023248, UL1RR024992)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioblastoma, molecular subtypes, proneural subtype, mesenchymal subtype, classical subtype, PDGFRA, IDH1, EGFR, neurofibromatosis type 1, somatic mutations, gene expression signatures, neural lineage, treatment response, molecular stratification
- MeSH terms
- Adult, Aged, Brain Neoplasms, DNA Mutational Analysis, Factor Analysis, Statistical, Glioblastoma, Humans, Isocitrate Dehydrogenase, Middle Aged, Mutation, Neurofibromatosis 1, Prognosis, Gene Expression, Gene Dosage, Oligonucleotide Array Sequence Analysis, Receptor, Platelet-Derived Growth Factor alpha, Gene Expression Profiling, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
